Research Topics
| Lisa A CareySummaryAffiliation: University of North Carolina Country: USA Publications
| Collaborators
|
Detail Information
Publications
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey
Hematology Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, 170 Manning Dr, Chapel Hill, NC 27599 7305, USA
J Clin Oncol 30:2615-23. 2012..Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy...- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabNancy U Lin
Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
Breast Cancer Res Treat 133:1057-65. 2012..4%) and rash (9.8%). Afatinib monotherapy was associated with promising clinical activity in extensively pretreated HER2-positive breast cancer patients who had progressed following trastuzumab treatment... - An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancerAndrea H Bild
Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA
Breast Cancer Res 11:R55. 2009..Additional work has also used signatures of oncogenic pathway deregulation to dissect breast cancer heterogeneity as well as to suggest therapeutic opportunities linked to pathway activation... 
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyLisa A Carey
Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
JAMA 295:2492-502. 2006..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...- The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesLisa A Carey
Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
Clin Cancer Res 13:2329-34. 2007..Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes... 
Directed therapy of subtypes of triple-negative breast cancerLisa A Carey
University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
Oncologist 15:49-56. 2010..This article addresses the nature of, and therapeutic strategies for, triple-negative breast cancer...- American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcomeLisa A Carey
Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7305, USA
J Natl Cancer Inst 97:1137-42. 2005.... - Central nervous system metastases in women after multimodality therapy for high risk breast cancerLisa A Carey
Division of Hematology Oncology, Department of Medicine, University of North Carolina, 3009 Old Clinic Building, Chapel Hill, NC, 27599 7305, USA
Breast Cancer Res Treat 88:273-80. 2004..This increase may reflect altered failure patterns from adjuvant therapy, more effective systemic therapy with improved control in non-CNS sites, or a resistant breast cancer subtype... - Directed therapy of subtypes of triple-negative breast cancerLisa A Carey
University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
Oncologist 16:71-8. 2011..This article addresses the nature of, and therapeutic strategies for, triple-negative breast cancer... - Through a glass darkly: advances in understanding breast cancer biology, 2000-2010Lisa A Carey
Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
Clin Breast Cancer 10:188-95. 2010..These include the need for more tissue-based studies to allow us to understand the mechanisms of sensitivity and resistance within and across subtypes, and the need to revisit risk and prevention by subtype... - Axillary lymph node count is lower after neoadjuvant chemotherapyHeather Neuman
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Am J Surg 191:827-9. 2006..6/170 or 4%, P = .003). CONCLUSIONS: A low lymph node count is more common in patients after treatment with neoadjuvant chemotherapy and should not be assumed to represent an incomplete ALND... - Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamideHanna Kelly
Department of Medicine, University of North Carolina at Chapel Hill, NC 27599-7305, USA
Clin Breast Cancer 7:237-43. 2006..CONCLUSION: In this study, the AC-TP regimen resulted in a high clinical but moderate pathologic response rate, and although asymptomatic cardiac systolic dysfunction was common, most of the severe decreases recovered over time... - Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognosticNancy Klauber-Demore
Department of Surgery, University of North Carolina at Chapel Hill, 27599, USA
Ann Surg Oncol 13:685-91. 2006..We examined the residual lymph node metastasis size in patients after treatment with neoadjuvant chemotherapy to determine the relevance of metastasis size on outcome... - Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancerWilliam J Irvin
The Lineberger Comprehensive Cancer Center, and Division of Hematology Oncology, School of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA
Clin Breast Cancer 10:465-70. 2010.... - A compact VEGF signature associated with distant metastases and poor outcomesZhiyuan Hu
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
BMC Med 7:9. 2009..Tumor metastases pose the greatest threat to a patient's survival, and thus, understanding the biology of disseminated cancer cells is critical for developing effective therapies... - Knowledge of genomic testing among early-stage breast cancer patientsAlice R Richman
Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA
Psychooncology 20:28-35. 2011..Genomic recurrence risk test results now inform clinical decisions about adjuvant treatment for women with early-stage breast cancer. We sought to understand patients' knowledge of these tests and correlates of their knowledge... - Women's interest in gene expression analysis for breast cancer recurrence riskSuzanne C O'Neill
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
J Clin Oncol 25:4628-34. 2007..We assessed interest in genomic RFR testing and patient preferences for incorporating results into treatment decision making... - The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of lifeE Forrest Morrill
The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Psychooncology 17:948-53. 2008.... - Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer StudyKatie M O'Brien
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Clin Cancer Res 16:6100-10. 2010.... - Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastasesBarbara Adamo
Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
Breast Cancer Res 13:R125. 2011..Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR) and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative BCBMs... 
EGFR associated expression profiles vary with breast tumor subtypeKatherine A Hoadley
Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
BMC Genomics 8:258. 2007..An EGFR-associated gene expression signature was identified in the basal-like SUM102 cell line and was used to classify a diverse set of sporadic breast tumors...- Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancerMichael O Meyers
Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA
Ann Surg Oncol 18:2851-7. 2011..The impact of subtypes on locoregional recurrence (LRR) after neoadjuvant chemotherapy for locally advanced breast cancer is unknown... - Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancersDavid W Ollila
Division of Surgical Oncology, Department of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA
Am J Surg 190:371-5. 2005..LM/SL in patients with large breast cancers is controversial. We examined the accuracy of LM/SL prior to neoadjuvant chemotherapy in patients with large (>3.5 cm) breast cancers... - Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility studyElizabeth Bullitt
Computer Assisted Surgery and Imaging Laboratory, University of North Carolina, 247 Wing E, CB 7062, Chapel Hill, NC 27599, USA
Radiology 245:824-30. 2007.... - Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signaturesCheng Fan
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
BMC Med Genomics 4:3. 2011..We evaluated whether combining the prognostic powers of standard breast cancer clinical variables with a large set of gene expression signatures could improve on our ability to predict patient outcomes... - The molecular portraits of breast tumors are conserved across microarray platformsZhiyuan Hu
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
BMC Genomics 7:96. 2006..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list... - When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapyNoel T Brewer
Department of Health Behavior and Health Education, University of North Carolina, Chapel Hill, 27516, USA
Breast Cancer Res Treat 117:25-9. 2009..We examined how women incorporate potentially differing genomic and standard assessments of breast cancer recurrence risk into chemotherapy decisions... - Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rateRaeshell S Sweeting
Division of Surgical Oncology, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, North Carolina, USA
Am Surg 77:850-5. 2011..This suggests that neoadjuvant chemotherapy may identify young women for whom BCT may have an acceptable risk of LRR... - Improving communication of breast cancer recurrence riskNoel T Brewer
Department of Health Behavior and Health Education, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599 7440, USA
Breast Cancer Res Treat 133:553-61. 2012..A less complex report, potentially including the risk continuum format, would be more effective in communicating test results to patients... - Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized studyMatthew J Ellis
Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
JAMA 302:774-80. 2009..Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy... - Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survivalWilliam G Cance
Department of Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599, USA
Ann Surg 236:295-302; discussion 302-3. 2002..The authors determined the rate of breast preservation, the disease-free and overall survival, and the factors associated with locoregional and distant recurrent disease... - Women's experiences with genomic testing for breast cancer recurrence riskJanice P Tzeng
Department of Health Behavior and Health Education, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Cancer 116:1992-2000. 2010..This study examined how women receive and incorporate results of Oncotype DX, a genomic test that offers recurrence risk estimates, into decisions about adjuvant treatment for early stage breast cancer... - The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastasesCarey K Anders
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
Cancer 117:1602-11. 2011..In a single-institution cohort study, the authors attempted to determine whether the inferior outcome noted with TNBC brain metastases is more reflective of a higher risk population or the subtype itself... - Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trialJohn A Olson
Department of Surgery, Duke Comprehensive Cancer Center, Durham, NC, USA
J Am Coll Surg 208:906-14; discussion 915-6. 2009..A multicenter phase II clinical trial was conducted to investigate the value of this approach for US surgical practice... - A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumorsE Claire Dees
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Cancer Chemother Pharmacol 63:99-107. 2008..We conducted a phase I trial of bortezomib and pegylated liposomal doxorubicin (PLD) in patients with refractory solid tumors... - CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxelDaniel L Hertz
UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, 120 Mason Farm Road, CB 7361, Chapel Hill, NC 27599, USA
Breast Cancer Res Treat 134:401-10. 2012..Patients carrying CYP2C8*3 are more likely to achieve clinical complete response from neoadjuvant paclitaxel treatment, but may also be at increased risk of experiencing severe peripheral neurotoxicity... - Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancerCarey K Anders
University of North Carolina, Chapel Hill, 27517, USA
Clin Cancer Res 16:4702-10. 2010.... - Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter studyWilliam J Irvin
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
J Clin Oncol 29:3232-9. 2011.... - Molecular subtypes in breast cancer evaluation and management: divide and conquerJeffrey Peppercorn
University of North Carolina, Chapel Hill, North Carolina, USA
Cancer Invest 26:1-10. 2008 - High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancerNancy Klauber-Demore
Department of Surgery, University of North Carolina at Chapel Hill, 3010 Old Clinic Bldg, CB No 7213, Chapel Hill, NC 27599, USA
Am J Surg 188:386-9. 2004..The purpose of this study was to evaluate the efficacy of high-resolution axillary ultrasound in detecting axillary lymph node metastases after neoadjuvant chemotherapy in patients with locally advanced breast cancer... - What is triple-negative breast cancer?William J Irvin
Department of Medicine, Division of Hematology Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
Eur J Cancer 44:2799-805. 2008..This review discusses the definitions and characteristics of as well as current and evolving therapies for triple-negative and basal-like breast cancer... - Estrogen-regulated genes predict survival in hormone receptor-positive breast cancersDaniel S Oh
Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
J Clin Oncol 24:1656-64. 2006..CONCLUSION: This study provides new biologic information concerning differences within hormone receptor-positive breast cancers and a means of predicting long-term outcomes in tamoxifen-treated patients... - CYP2D6 and tamoxifen: DNA matters in breast cancerJanelle M Hoskins
UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, 27599, North Carolina, USA
Nat Rev Cancer 9:576-86. 2009..Here we review the existing data that relate CYP2D6 genotypes to response to tamoxifen and discuss whether the analysis of the CYP2D6 genotype might be an early example of a pharmacogenetic tool for optimizing breast cancer therapy... - Biology, metastatic patterns, and treatment of patients with triple-negative breast cancerCarey K Anders
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, 27599, USA
Clin Breast Cancer 9:S73-81. 2009..Finally, the positive association between triple-negative breast cancer and BRCA mutations makes inhibition of poly(adenosine diphosphate-ribose) polymerase-1 an attractive therapeutic strategy that is in active study... - Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacySarah E Lillie
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Cancer Epidemiol Biomarkers Prev 16:249-55. 2007..Because these genomic tests are so new, little is known about how well patients understand the tests and their results... - Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancerE Claire Dees
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Campus Box #7295, Chapel Hill, NC 27599-7295, USA
Cancer Immunol Immunother 53:777-85. 2004..CONCLUSIONS: This approach is safe and effective in generating a significant quantity of DCs from CD34-precursors... - Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local controlMatthew G Ewend
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Clin Cancer Res 13:3637-41. 2007..To define the safety and efficacy of carmustine polymer wafers when added to a regimen of surgery and external beam radiotherapy for treatment of a single brain metastasis... - Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapyMatthew G Ewend
Division of Neurosurgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
J Natl Compr Canc Netw 6:505-13; quiz 514. 2008.... - Understanding and treating triple-negative breast cancerCarey Anders
Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
Oncology (Williston Park) 22:1233-9; discussion 1239-40, 1243. 2008.... - Gene expression profiling in breast cancerShannon R Morris
GlaxoSmithKline, Research Triangle Park and Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
Curr Opin Oncol 19:547-51. 2007..The review is intended to highlight the most important advances in the field over recent years with an emphasis on those most relevant to the practicing oncologist... - Clinical trials in triple negative breast cancerKatherine E Reeder-Hayes
Department of Hematology Oncology, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA
Breast Dis 32:123-36. 2010.... - Reporting of race and ethnicity in breast cancer research: room for improvementKelly W Mitchell
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Breast Cancer Res Treat 118:511-7. 2009..Low accrual of black subjects and failure to report accrual and outcomes by race in RCT may contribute to difficulty in understanding and overcoming health disparities in breast cancer... - Quantifying the recruitment challenges with couple-based interventions for cancer: applications to early-stage breast cancerSteffany J Fredman
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Psychooncology 18:667-73. 2009.... - Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancerElizabeth Bullitt
CASILab, CB 7062, University of North Carolina, Chapel Hill, NC 27599, USA
Med Image Comput Comput Assist Interv 9:561-8. 2006..In this preliminary study of 16 patients undergoing treatment for metastatic breast cancer we conclude that vessel shape may predict tumor response several months in advance of traditional methods... - Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patientsErick Roman-Perez
Department of Epidemiology, University of North Carolina at Chapel Hill, Campus Box 7435, Chapel Hill, NC 27599, USA
Breast Cancer Res 14:R51. 2012..We hypothesized that gene expression subtypes of breast cancer microenvironment can be defined and that these microenvironment subtypes have clinical relevance... - Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer riskWilliam K Kaufmann
Lineberger Comprehensive Cancer Center, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Carcinogenesis 27:2519-27. 2006..This study tested whether sporadic breast cancer was associated with constitutive radiation hypersensitivity... - Molecular profiling in breast cancerShannon R Morris
GlaxoSmithKline, Research Triangle Park, NC, USA
Rev Endocr Metab Disord 8:185-98. 2007..The increasingly sophisticated understanding allowed by this and similar technology promises future individualized therapy... - Gene-expression analysis and the basal-like breast cancer subtypeTimothy J Finnegan
The University of North Carolina, Division of Hematology Oncology, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA
Future Oncol 3:55-63. 2007..This review discusses the molecular profiles of breast cancer with a focus on the clinical characteristics of, and treatment options for, the basal-like subtype... - Adjuvant systemic therapy in young womenDaniel R Carrizosa
Division of Hematology/Oncology, University of North Carolina at Chapel Hill, 27599-7305, USA
Breast Dis 23:67-71. 2005.... - Current treatment paradigms for the management of patients with brain metastasesMatthew G Ewend
Division of Neurological Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7060, USA
Neurosurgery 57:S66-77; discusssion S1-4. 2005..With advances in systemic therapy for cancer, the treatment of brain metastases is becoming an increasingly important determinant of the length of survival and quality of life for cancer patients... - Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancerShannon R Morris
GlaxoSmithKline, Research Triangle Park, North Carolina, USA
Oncology (Williston Park) 20:1763-71; discussion 1771-2, 1774-6. 2006..Overcoming that resistance to therapy is our next challenge. This review examines the current understanding of HER2 biology, the mechanisms of action of and resistance to trastuzumab, as well as new therapies on the horizon... - Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancerBeth O Van Emburgh
Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
Mol Carcinog 47:88-99. 2008.... - Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancerErica L Mayer
Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Breast Cancer Res 9:110. 2007..Ongoing studies of novel agents may lead to improved therapeutic outcomes for this high-risk population... - Research issues affecting preoperative systemic therapy for operable breast cancerAntonio C Wolff
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 189, Baltimore, MD 21231 1000, USA
J Clin Oncol 26:806-13. 2008..PST requires an experienced and cohesive multidisciplinary team for it to fulfill its potential in both research and clinical care... - Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancerNancy U Lin
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 26:1993-9. 2008..We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases... - Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancerBritta Weigelt
Divisions of Experimental Therapy and Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands
Cancer Res 65:9155-8. 2005..Furthermore, our data imply that poor prognosis breast carcinomas classified either by the intrinsic gene set or the 70 prognosis genes represent distinct disease entities that seem sustained throughout the metastatic process... - Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancerBeth O Van Emburgh
Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Oncol Rep 19:1311-21. 2008..97; 95% CI=1.27-12.40). These results suggest the importance of estrogen/carcinogen metabolic enzymes in the etiology of breast cancer, especially in women before the age of 60, as well as preventative measures such as smoking cessation... - Molecular classification and molecular forecasting of breast cancer: ready for clinical application?James D Brenton
Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Centre, Cambridge, United Kingdom CB22XZ
J Clin Oncol 23:7350-60. 2005....